IMUGENE CHART. TA only, page-18205

Any company with a high quality BOD woukd waste and time or money looking for a TGA approval. The TGA and the APVMA are bureaucratic swamps. And the Australian market is too small to waste time on.

IMU will get their platforms approved very quickly by the FDA. And the EU approvals will be fast also. IMU’s products are accumulating massive safety data. That’s the biggest hurdle. Efficacy will be very easy to prove up. IMU is not chasing a 5% improvement on the SOC. They are obliterating solid tumors. We can watch this live on a PET SCAN.

What we s going in IMU ‘s favour here is the massive unmet need. There is zero safe options providing effective treatments for solid tumors. That’s where the estimated US$450-$900bn PA market opportunity lies.

Fo those here suffering from frustration with the disconnect between scientific progress and shareprice progress, you can relax knowing that LC is putting in 10X more effort into raising awareness with Big Pharma and Big Biotech than she is with shareholders. And she does an amazing job of keeping shareholders updated.

When the time is right this company will reflect true value very rapidly. LC has already laid out the timeline for this . “In the next 6-12 months we will rock the world “. That’s the timeframe. We could expect some movement before then, as early buyers get set.

When the IMU/Celularity/Eureka deal becomes “front page news” , it will alert NASDAQ investors to this very disruptive technology. Seems like disruptive technologies stay flat for a very long time and then explode. That’s what Ben calls the tipping point.